ESR1 overexpression is a biomarker of relapse and worse prognosis in stage I endometrioid endometrial carcinoma.

ABSTRACT: Endometrial cancer (EC) is the most common pelvic gynecologic malignancy in developed countries, and its incidence is also increasing in developing countries. Endometrioid endometrial carcinoma (EEC) is the most frequent subtype. EEC is often associated with favorable clinicopathological features and a good prognosis, especially when diagnosed in stage I. Although some patients have no signs to predict locally advanced or metastatic disease, they may present tumor relapse in the future. There is no biomarker capable of predicting the relapse of stage I EEC. The present study applied a transcriptome analysis to identify differentially expressed genes in stage I EEC, comparing relapsed with non-relapsed tumors. The estrogen receptor 1 gene (ESR1) was overexpressed in EEC stage I samples from

SUBMITTER: Chaves CBP 

PROVIDER: S-EPMC12068764 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature